| Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway K Lee, MG Evans, L Yang, S Ng, C Snowden, M Khodadoust, RA Brown, ... Blood, The Journal of the American Society of Hematology 138 (23), 2435-2440, 2021 | 17 | 2021 |
| An ErbB2 splice variant lacking exon 16 drives lung carcinoma HW Smith, L Yang, C Ling, A Walsh, VD Martinez, J Boucher, D Zuo, ... Proceedings of the National Academy of Sciences 117 (33), 20139-20148, 2020 | 16 | 2020 |
| Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells Y Jia, L Han, CL Ramage, Z Wang, CC Weng, L Yang, S Colla, H Ma, ... Haematologica 108 (10), 2626, 2023 | 15 | 2023 |
| Archival single-cell genomics reveals persistent subclones during DCIS progression K Wang, T Kumar, J Wang, DC Minussi, E Sei, J Li, TM Tran, ... Cell 186 (18), 3968-3982. e15, 2023 | 15 | 2023 |
| Oncogenic KRAS drives lipofibrogenesis to promote angiogenesis and colon cancer progression WH Hsu, KA LaBella, Y Lin, P Xu, R Lee, CE Hsieh, L Yang, A Zhou, ... Cancer discovery 13 (12), 2652-2673, 2023 | 14 | 2023 |
| Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1 W Wu, GM Nelson, R Koch, KA Donovan, RP Nowak, TB Heavican-Foral, ... Blood, The Journal of the American Society of Hematology 139 (13), 2024-2037, 2022 | 14 | 2022 |
| Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma JD Soumerai, A Rosenthal, S Harkins, J Duffy, C Mecca, Y Wang, ... Blood, The Journal of the American Society of Hematology 140 (16), 1822-1826, 2022 | 8 | 2022 |
| Peroxisome proliferator‐activated receptors as therapeutic target for cancer Y Wang, F Lei, Y Lin, Y Han, L Yang, H Tan Journal of Cellular and Molecular Medicine 28 (5), e17931, 2024 | 2 | 2024 |
| New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation ML Arwood, Y Liu, SK Harkins, DM Weinstock, L Yang, KE Stevenson, ... Cell chemical biology 30 (6), 618-631. e12, 2023 | 2 | 2023 |
| KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas B Assatova, C Trevisani, R Willim, J Duffy, A Louissaint, WS Kim, DJ Feith, ... Blood 140 (Supplement 1), 2253-2255, 2022 | 1 | 2022 |
| Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells Y Jia, L Han, CL Ramage, CC Weng, L Yang, S Colla, H Ma, W Zhang, ... Blood 140 (Supplement 1), 3347-3349, 2022 | | 2022 |
| The role of ErbB2 and its splice variant in lung tumour progression L Yang McGill University, 2020 | | 2020 |
| Primary cytotoxic T-cell lymphomas harbor recurrent targetable K Lee, MG Evans, L Yang, S Ng, C Snowden, M Khodadoust, RA Brown, ... Blood, 0 | | |
David WeinstockProfessor of Medicine在 merck.com 的电子邮件经过验证
David WeinstockProfessor of Medicine在 merck.com 的电子邮件经过验证
Nicholas NavinMD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证
Wang KaileMD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证